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Abbreviations: 
CRP C-Reactive Protein 
CSF1R colony stimulating factor 1 receptor 
CTNNB1 catenin (cadherin-associated protein), beta 1 
EGFR epidermal growth factor receptor 
EP empty plasmid 
gp130 glycoprotein 130 
HCA hepatocellular adenoma 
HCC hepatocellular carcinoma 
HNF1α hepatocyte nuclear factors 1α 
IHCA inflammatory hepatocellular adenoma 
IL6ST interleukin 6 signal transducer 
Luc luciferase 
ORF open reading frame 
PDGFR platelet-derived growth factor receptors 
SAA serum amyloid A 
SH2 Src Homology 2 
siRNA small interfering RNA 
SOCS3 suppressor of cytokine signaling 3 
Src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
TAD transactivation domain 
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Abstract 
Inflammatory hepatocellular adenomas (IHCA) are benign liver tumors and 60% of these 
have IL6ST (gp130) mutations that activate interleukin 6 (IL-6) signaling. Here we report 
that 12% of IHCA subsets lacking IL6ST mutations harbor somatic STAT3 mutations 
(6/49). Most of these mutations are amino acid substitutions in the SH2 domain that 
directs STAT3 dimerization. In contrast to wild-type STAT3, IHCA STAT3 mutants 
constitutively activated the IL-6 signaling pathway independent of ligand in 
hepatocellular cells. Indeed, the IHCA STAT3 Y640 mutant homodimerized independent 
of IL-6 and was hypersensitive to IL-6 stimulation. This was associated with 
phosphorylation of tyrosine 705, a residue required for IL-6-induced STAT3 activation. 
Silencing or inhibiting the tyrosine kinases JAK1 or Src, which phosphorylate STAT3, 
impaired constitutive activity of IHCA STAT3 mutants in hepatocellular cells. Thus, we 
identified for the first time somatic STAT3 mutations in human tumors, revealing a new 
mechanism of recurrent STAT3 activation and underscoring the role of the IL-6-STAT3 
pathway in benign hepatocellular tumorigenesis. 
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Introduction 
 
Inflammatory hepatocellular adenomas (IHCA) are benign liver tumors that 
predominantly develop in women and that are frequently associated with obesity and 
alcohol abuse  (Bioulac-Sage et al., 2007; Zucman-Rossi et al., 2006). These tumors 
are characterized by overexpression of the acute-phase inflammatory response in tumor 
hepatocytes and highly polymorphous inflammatory infiltrates. We recently showed that 
60% of IHCA activate STAT3 (Signal Transducers and Activators of Transcription type 
3) via somatic heterozygous activating mutations in IL6ST that encodes the gp130 co-
receptor and signal transducer of IL-6 family cytokines (Rebouissou et al., 2009). 
Inflammatory adenoma is a homogenous disease, where gp130 mutated and 
non-mutated IHCAs are similar in their expression profiles, in particular regarding the 
expression of acute phase inflammatory response target genes (Rebouissou et al., 
2009). To identify genetic alterations causing the inflammatory phenotype, defined as an 
acute-phase inflammatory response with elevated levels of Serum Amyloid A (SAA) and 
C-Reactive protein (CRP) observed in non-mutated gp130 IHCA, we used a candidate 
gene strategy. We focused on STAT3 as it encodes a key nuclear transcription factor 
that induces the acute-phase inflammatory response in hepatocytes. Moreover, STAT3 
has oncogenic roles in epithelial cell tumorigenesis (Grivennikov et al., 2009; 
Grivennikov et al., 2010; Yu et al., 2009). STAT proteins are latent transcription factors 
activated by phosphorylation, typically following the binding of extracellular ligands to 
cytokine receptors that activate associated JAK kinases, via growth factor receptors 
having intrinsic tyrosine kinase activity (e.g., EGFR, PDGFR and CSF1R), as well as by 
non-receptor tyrosine kinases such as Src family kinases (Levy and Darnell, 2002). 
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STAT3, one of seven STAT family members, is activated by gp130 in response to 
interleukin-6 (IL-6) (Inoue et al., 1997; Zhong et al., 1994). STAT3 is persistently 
phosphorylated in many human cancer cell lines and in epithelial cells and primary 
tumors, including hepatocellular carcinoma, breast, prostate, and head and neck 
cancers, and also in several hematological malignancies. STAT3 mutations have never 
been described in human tumors, yet we reasoned that alterations activating its function 
would explain the inflammatory phenotype of IHCA lacking mutations in gp130. 
 
 
Results and Discussion  
 
Identification of STAT3 mutations in IHCA 
Among 114 screened hepatocellular adenomas, we identified seven STAT3 mutations in 
6 tumors (Table 1 and Supplementary Fig. S1a-b). All of these adenomas were 
inflammatory (6 out of 75 IHCA) and no additional somatic mutations were identified in 
HNF1A, CTNNB1 or IL6ST, genes recurrently altered in IHCA and HCA (Bluteau et al., 
2002; Rebouissou et al., 2009; Zucman-Rossi et al., 2006). Thus, STAT3 IHCA 
mutations are exclusive from all other known genetic alterations in hepatocellular 
tumors. STAT3 mutated IHCA were associated with obesity (n = 4) and/or alcohol abuse 
(n = 3) and multiple (≥4) nodules were present in half of these cases. All STAT3 
mutations were somatic, as they were not observed in adjacent non-tumor liver tissues 
that were steatotic in 5/6 cases. All mutations were also monoallelic and led to amino 
acid substitutions in 5 cases or to in-frame insertions of 1 to 4 amino acids in the 
remaining two cases. In one case (#379) we identified three nucleotide mutations that 
led to amino acid substitutions at codons 502 and 658. Sequencing cloned STAT3 
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cDNA from this tumor showed that the three different nucleotide mutations were carried 
by the same allele. We also showed in three different cases (#379, #966 and #1351) 
that the mutations were harbored by all of the isoforms of STAT3, including splicing of 
nucleotides 2099-2101 and 2145-2194 (STAT3β) that lead to p.Ser701del and 
p.Thr716PhefsX8, respectively (Supplementary Fig. S1c) (Schaefer et al., 1995). 
Sequencing STAT3 RT-PCR products in mutated tumors showed that all cases 
expressed the normal and mutated STAT3 alleles at comparable levels (Supplementary 
Fig. S1a-b). Thus, the expression of one mutated STAT3 allele is a rare but recurrent 
genetic event in IHCA that is selected for during benign hepatocellular tumorigenesis. 
Four of the seven identified mutations were located in the domain of STAT3 
(residues 585-688) that shares homology with Src-homology-2 (SH2) domains (Fig. 1a). 
The STAT3 SH2 domain mediates STAT3 dimerization via binding of phosphotyrosine 
residue Y705 (Shuai et al., 1994; Wen et al., 1995). Moreover, three of these mutations 
clustered in a hotspot in the SH2 domain at codons 657 and 658. Interestingly, 
introduction of cysteine at residues 662 and 664 promotes STAT3 dimerization and 
creates a constitutively active transcription factor (Stat3-C) (Bromberg et al., 1999). The 
fourth mutation, Y640F, was in the PYTK motif conserved in STAT1, STAT2 and 
STAT3. Interestingly, substitution of the corresponding Y631 to phenylalanine in STAT2 
promotes type I IFN signaling (Constantinescu et al., 2008; Scarzello et al., 2007). The 
three other mutations found in IHCA were distributed throughout the protein; the altered 
leucine-78 that contributes to dimerization (Chen et al., 2003), glutamate-166 that is part 
of helix 1 involved in the interaction with gp130 (Zhang et al., 2000a) and aspartate-
502 that is located in the -helical “connector” domain. Remarkably, none of the 
STAT3 mutations in hepatocellular adenoma 7 
mutations identified in IHCA were similar to the 150 germline inactivating STAT3 
heterozygous mutations described in patients with Job’s syndrome that causes the 
hyper-IgE syndrome (Holland et al., 2007; Minegishi et al., 2007). 
 
IHCA mutations activate STAT3 in absence of IL-6 
To investigate possible functional consequences of these STAT3 IHCA mutations, we 
introduced the seven different IHCA mutations into a STAT3α (full length) cDNA and 
analyzed their effects in Hep3B cells, a hepatocellular carcinoma line that activates the 
acute inflammatory phase following treatment with IL-6 (Coulouarn et al., 2005). The 
results were also validated in two additional hepatocellular cell lines (HepG2 and Huh7). 
As described (Bromberg et al., 1999), in the absence of IL-6 ligand and serum, 
overexpression of wild-type STAT3 (WT) alone was not sufficient to activate a STAT3 
reporter (Fig. 1b) nor the downstream acute-phase inflammatory genes (Fig. 1c). In 
contrast, the six IHCA mutants and the mouse Stat3-C mutant (Bromberg et al., 1999) 
activated the STAT3 reporter in the absence of IL-6 and induced targets typical of the 
acute inflammatory response, including CRP and SOCS3 (Fig. 1b and 1c). Moreover, 
activation of STAT3 was proportional to the amount of the transfected mutant STAT3 
(Fig. 1d). The last IHCA mutant D502Y/K658Y, identified in tumor #379, has two 
mutations on the same allele. The D502Y mutation did not impart constitutive activity, 
whereas K658Y activated the inflammatory response. Further, the dual mutant (D502Y + 
K658Y) produced a hyperactive STAT3 mutant compared to K658Y alone (Fig. 1e). 
Thus, mutation at D502 alone is not sufficient to activate STAT3 but cooperates with the 
mutation at K658 present in the SH2 domain. 
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IHCA STAT3 mutants are constitutively phosphorylated on Tyr705 and translocate 
to the nucleus 
STAT3 activation requires phosphorylation of tyrosine 705, dimerization and 
translocation to the nucleus. Accordingly, in STAT3 mutated IHCA, 
immunohistochemical analyses demonstrated marked overexpression of phospho-
Tyr705-STAT3 in the nucleus of these tumor hepatocytes (Fig. 2a). Similarly, in Hep3B 
transfected cells, we showed that STAT3 mutants L78R, E166Q, Y640F and 
G656_Y657insF were constitutively phosphorylated on Tyr705 and translocated to the 
nucleus, whereas overexpressed wild-type STAT3 was unphosphorylated and 
cytoplasmic in the absence of cytokine (Fig. 2b-d). STAT3 IHCA mutants did not exhibit 
increased phosphorylation of serine 727, a second residue also involved in STAT3 
activation (Wen et al., 1995), when compared to IL-6 activated wild-type STAT3 
(Supplementary Fig. S2a). Moreover, in STAT3 Y640 and G656 mutants substitution of 
tyrosine 705 with phenylalanine totally abrogated activation of the inflammatory 
response. Thus, tyrosine phosphorylation is essential for activation of IHCA mutant 
STAT3 (Fig. 2e).  
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IHCA STAT3 mutants dimerize in absence of cytokine 
A critical step in STAT3 activation is the formation of homodimers through reciprocal 
phospho-Tyr705-SH2 domain interactions. To assess dimerization by IHCA STAT3 
mutants, we performed co-immunoprecipitation assays with epitope-tagged STAT3 
proteins. The Y640F mutant homodimerized or heterodimerized with wild-type STAT3 
independent of IL-6 (Fig. 3a). Moreover, mutant homodimers were highly 
phosphorylated at tyrosine 705. In contrast, homodimers of wild-type STAT3 were only 
faintly detected and were not phosphorylated on tyrosine 705. As expected, IL-6 
treatment does not enhance dimer formation, but slightly increases tyrosine 705 
phosphorylation (Haan et al., 2000). In addition, overexpression of wild-type STAT3 
impaired the activity of the STAT3 mutant Y640F in a dose dependent manner (Fig. 3b). 
Thus, wild-type STAT3 can compete with the mutant STAT3 and impair the formation of 
active IHCA mutant homodimers. Interestingly, analysis of the STAT3 homodimer 
structure (Becker et al., 1998) showed that 4 out of 6 STAT3 mutants targeted amino 
acids (Y640, K658, Y657 and Y657-M660) that reside near the transcription activation 
domain (TAD, residues 701-722) (Fig. 3c and Supplementary Fig. S2b). For example, 
Tyr-640 engages in hydrophobic interactions with two-fold related Phe-710 and residues 
656-659 pack against TAD residues 711-716 (Fig. 3c and Supplementary Fig. S2b). 
These modifications could thus enhance mutant STAT3 function, and they must also 
somehow facilitate phosphorylation of tyrosine 705 by kinases in hepatocytes, which 
would then drive dimerization and nuclear localization of mutant STAT3. Following 
cytokine exposure, phosphorylated STAT3 homodimers translocate to the nucleus 
where they bind to specific IL-6 responsive elements to activate the transcription of 
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target genes (Hattori et al., 1990). In Hep3B cells, nuclear Y640 and G656 STAT3 
mutants bind to recognition elements found in endogenous STAT3 target genes in the 
absence of IL-6 whereas, as expected, wild-type STAT3 was defective in binding in the 
absence of IL-6 (Fig. 3d).  
 
IHCA STAT3 mutants are hyper-responsive to IL-6 
To investigate the role of the IL-6-JAK pathway in the activation status of IHCA STAT3 
mutants, we tested the effects of increasing doses of IL-6 on their activity. Indeed, even 
low doses of IL-6 (1 ng/ml) dramatically augmented the constitutive activity of the Y640 
STAT3 mutant when compared to the wild-type STAT3 (Fig. 4a). This hypersensitive 
response to IL-6 signaling was confirmed for L78, E166, G656 and Y657 STAT3 
mutants (Fig. 4b and Supplementary Fig. S2c). Together with gp130, JAK1 is known as 
the major kinase that phosphorylates and activates STAT3 in IL-6 signaling. 
Accordingly, silencing JAK1 by siRNA abolished the hyper-stimulation of the STAT3 
mutants by IL-6 (Fig. 4b).  
 
Activity of IHCA STAT3 mutants requires Src  
In the absence of IL-6 signaling, silencing of gp130 or JAK2 did not affect the 
constitutive activity of IHCA STAT3 mutants (Fig. 4c-d). In contrast, JAK1 knockdown by 
siRNA partially impaired constitutive IHCA STAT3 mutant activity (Fig. 4e). Similarly, 
AG490, an inhibitor that disables the kinase activity of both JAK1 and JAK2, Ruxolitinib, 
a selective inhibitor of Jak1, and curcumin, a STAT3 inhibitor, partially decreased the 
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activity of IHCA STAT3 mutants (Supplementary Fig. S3a-b). In contrast, treatment with 
SrcI-1 kinase inhibitor dramatically impaired both the constitutive and IL-6 induced 
activation of IHCA STAT3 mutants (Fig. 4f and Supplementary Fig. S3c). Two other Src 
kinase inhibitors also impaired the activity of IHCA STAT3 mutants (Supplementary Fig. 
S3d-e). Thus, phosphorylation and activation of mutant STAT3 does not require gp130 
or JAK2 but requires JAK1 and Src signaling. Depending on cell context, STAT3 can be 
activated directly by Src family kinases or via Jak1 (in NIH 3T3 cells) as an intermediate 
kinase between Src and STAT3 (Zhang et al., 2000). Our findings suggest that in 
hepatocellular cell lines, the requirement of Jak1 is necessary for maximal activation of 
IHCA STAT3 mutants, whereas Src is essential for their constitutive activation. 
 
STAT3-mutated IHCA are similar to gp130-mutated IHCA 
In vivo, expression analyses of 16 IHCA revealed no significant differences in 28 target 
genes of IL-6 and interferon signalling pathways in STAT3 mutated adenomas (n=5) 
versus gp130 mutated IHCA (n = 11; Fig. 4g). Thus, the functional effects of mutating 
STAT3 and gp130 in human hepatocellular adenomas appear redundant.  
In the liver, activation of the IL-6-STAT3 signaling is necessary for the acute-phase 
response during inflammation (Lutticken et al., 1994) and liver regeneration, particularly 
following transplantation (Cressman et al., 1996). The connection between inflammation 
and tumorigenesis has been extensively investigated over the past decade (see ref. 
(Grivennikov and Karin, 2010) for review). Depending of the model, inflammation can 
trigger tumor initiation or function to enhance tumor progression and/or metastasis. 
During these processes and in numerous tumor types, STAT3 activation has been 
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recognized as a major oncogenic event. However, in our cohort, STAT3 activating 
mutations are found in 8% of the inflammatory hepatocellular adenoma, but were not 
present in a series of 218 malignant liver tumors, including hepatocellular carcinomas 
and cholangiocarcinomas (n = 11). Thus, STAT3 activating mutations appear to be 
largely or quasi-exclusively associated with benign proliferation of hepatocytes in 
human.  
Collectively our findings show that most of the genetic alterations of HCA subtypes, 
(HNF1A inactivation, ß-catenin activation or activation of STAT3 via mutation of STAT3 
or gp130), are associated with benign hepatocyte tumorigenesis, where there remains a 
largely controlled rate of tumor cell proliferation. At present, only ß-catenin activating 
mutations are associated with malignant transformation to hepatocellular carcinoma 
(Zucman-Rossi et al., 2006), and here there are likely additional cooperating mutations 
that lead to frank malignancy. Regardless, to our knowledge this is the first identification 
of somatic mutation of STAT3 in human tumors, and these findings underscore the 
important role of STAT3 activation in hepatocellular benign tumorigenesis and reveal a 
new mechanism of recurrent STAT3 activation. 
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Materials and Methods 
 
Tumors and Patients 
A series of 364 hepatocellular tumors including 114 hepatocellular adenoma (HCA), 218 
common hepatocellular carcinoma (HCC), 11 cholangiocarcinomas and 20 
hepatocholangiocarcinomas were previously collected (according to French ethical 
guidelines) and characterized (Bioulac-Sage et al., 2007; Zucman-Rossi et al., 2006). 
Briefly, patients with HCA were predominantly female (80%) with a mean age of 39 
years; among them 13% presented mutations of CTNNB1 gene, 19% of HNF1α, 26% 
displayed IHCA-associated IL6ST mutations, 39.5% showed IHCA without IL6ST 
mutations and 9.6% were non classified adenomas. Patients with HCC were 
predominantly male (79%), with a mean age of 64 years, and 34.3% of these presented 
with cirrhosis. The underlying risk factors of patients with HCC were chronic hepatitis B 
(19%), chronic hepatitis C (25%) and heavy alcohol intake (38%). Patients with 
cholangiocarcinoma were predominantly male (72%) and were slightly younger (mean 
age: 61 years) than patients with common HCC. Patients with 
hepatocholangiocarcinoma were also predominantly male (89%) and had a median age 
of 61 years. All patients have given consent according to French law, and the ethical 
committee of Saint Louis Hospital approved the study.  
Tumor and non-tumor liver samples were frozen immediately after surgery or 
biopsy and stored at –80°C. Tissues samples were also included in 10% formalin, 
paraffin-embedded and stained with haematin-eosin and masson trichrome. The 
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diagnosis of HCA, HCC, cholangiocarcinoma and hepatocholangiocarcinoma was 
performed on established histological criteria (1995).  
 
Quantitative RT-PCR  
Quantitative RT-PCR was performed as described (Rebouissou et al., 2009) using pre-
designed primers and probe sets from Applied Biosystems (listed in Supplementary 
Table S1). Ribosomal 18S RNA (R18S) was used to normalize expression data and the 
2-∆∆CT method was apllied. 
 
DNA sequencing 
DNA sequencing was performed as described (Rebouissou et al., 2009) using primers 
described in Supplementary Table S2. All HCA samples were previously sequenced for 
CTNNB1 (exons 2-4), HNF1A (exons 1-10), and IL6ST (exon 6). All HCC samples were 
previously sequenced for CTNNB1 (exons 2-4) and P53 (exons 2-10) as described 
(Rebouissou et al., 2009; Zucman-Rossi et al., 2006). All mutations were validated by 
sequencing a second independent PCR product on both strands. In all cases the 
somatic origin of the mutation found in tumor was verified by sequencing the 
corresponding adjacent, normal liver sample.  
 
Generation of STAT3 mutants 
A full-length STAT3 open reading frame cloned in pCMV6-XL4 vector was purchased 
from OriGene (SC124165, NM_139276). Mutagenesis reactions were performed using 
the QuickChange XL site-directed mutagenesis kit (Stratagene) using primers described 
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in Supplementary Table S3. All constructs were verified by sequencing. The pCMV6-
XL4 expression vector plasmid was used as a control. Stat3-C plasmid was purchased 
from Addgene, Inc. (plasmid 8722). 
 
Cell culture 
Hep3B, Huh7 and HepG2 cells (ATCC) were grown in DMEM containing 10% FCS 
supplemented with penicillin (100 units/mL) and streptomycin (0.1 mg/mL). For 
transfections, cells were plated 16 hr prior to transfection to produce monolayers that 
were 60% confluent, and these were transfected by using either Lipofectamine™ LTX 
(plasmid alone) or Lipofectamine™ 2000 (plasmid and siRNA) according to the 
manufacturer’s instructions (Invitrogen). Transfection efficiency was monitored by 
measuring the level of either wild-type and mutated STAT3 mRNA using quantitative 
RT-PCR or western blot analysis. The same STAT3 expression level was observed in 
wild-type STAT3 and IHCA mutant STAT3 transfected cells. For luciferase assays, 
Hep3B cells were co-transfected with a STAT3 luciferase reporter expressing a firefly 
luciferase reporter gene that contains three copies of a STAT3 consensus binding site 
linked to a minimal thymidine kinase promoter (kindly provided by Dr. H. Gascan, Institut 
National de la Santé et de la Recherche Médicale UMR564, Angers, France) (pSIEM-
Luc 1μg, (Coqueret and Gascan, 2000)) and the expression plasmid for wild-type or 
IHCA mutant STAT3 (1μg).  One day after transfection, cells were starved in a free-
serum medium for 3 hr, then left untreated or treated with IL-6 (100 ng/ml) for 3 hr, and 
they were then lysed and the luciferase activity determined according to the 
manufacturer’s recommendations (Promega). The activities were normalized to the 
protein amounts in each cell lysate. All analyses were performed in triplicate. 
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Knockdown with siRNA 
The efficiency of knockdown using siRNAs was monitored by measuring the level of 
either JAK1, JAK2 or IL6ST mRNA using quantitative RT-PCR (Supplementary Fig. S3f) 
or by western blot analysis. Knockdown efficiency was greater than 80%. JAK1 siRNA 
(S7646), JAK2 siRNA (S7651) and IL6ST (gp130) siRNA (S229006) were purchased 
from Applied Biosystems; siRNA control (Block-IT Alexa Fluor Red) was purchased from 
Invitrogen.  
 
Pharmacological treatments 
Cells were exposed, in serum-free medium, for 6 hr to Tyrphostin AG490 (Sigma 
France), 9 hr to Src Inhibitor-1 (Sigma France), Src Inhibitor-5 (JS Res Chemical 
Trading, Germany) or PP2 (Sigma), 18 hr to Ruxolitinib (INCB-018424, JS Res 
Chemical Trading, Germany) and 24 hr to Curcumin (Sigma). In the last 3 hr of 
treatment, cells were stimulated with IL-6 (100ng/ml), or not, as indicated.  
 
Western blot analysis 
Western blot analyses were performed as described (Rebouissou et al., 2009) using 
antibodies specific for STAT3 (Cell Signaling Technology, diluted 1:500) and phospho-
STAT3 Tyr705, (Cell Signaling Technology, diluted 1:200). For dimerization assays, cell 
lysates were incubated with Immobilized Protein G agarose (Pierce) and anti-flag (Cell 
signaling technology, 1:50) or anti-myc (Cell signaling technology, 1:200) antibody, at 
4°C overnight, prior to western blot analysis. 
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Immunohistochemistry 
Immunohistochemistry was performed using a Dako autostainer, on paraffin sections of 
10% fixed tumor tissue using a monoclonal anti-phospho-STAT3 Tyr705 (Cell Signaling 
Technology, 1:50). For each immunohistochemical procedure, antigen retrieval was 
performed in citrate buffer, detection was amplified by the Dako Envision system. 
 
STAT3 DNA-binding assays 
One day after transfection, cells were starved in a serum-free medium overnight, and 
the TransFactor Extraction Kit (Clontech Inc.) was used to prepare nuclear extracts 
following the manufacturer's protocol. Nuclear extracts were analyzed for STAT3 DNA 
binding activity using the TransFactor Universal STAT3-specific kits (Clontech Inc.), 
which is an ELISA-based method. 
 
Immunofluorescence 
24 hr after transfection cells were fixed in 4% formaldehyde for 15 min, washed with 
phosphate-buffered saline (PBS), then permeabilized with 0.1% triton for 15 min. Cells 
were saturated with 2% BSA for 30 min, washed with PBS, then incubated with primary 
antibody overnight at 4°C. After three washes with PBS, cells were incubated with 
secondary antibodies for 1 hr. The slides were washed, then mounted with 
VECTASHIELD® Mounting Medium with DAPI (Vector labs). Immunofluorescence 
images were obtained using a Carl Zeiss HBO 100 optic microscope. All data from one 
experiment were collected at the same intensity and background level. The following 
monoclonal antibodies were used: rabbit anti-phospho-STAT3 Tyr705 (Cell Signaling 
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Technology, 1:200), mouse anti-total STAT3 (Cell Signaling Technology, 1:100) and the 
secondary antibodies were anti-mouse (Invitrogen, 1:200) and anti-rabbit (Invitrogen, 
1:200). 
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Figure 1. Gain-of-function mutations in STAT3 in IHCA. a, Distribution of STAT3 
mutations identified in IHCA are represented according to the different protein domains 
(SH2: Src-homology-2 domain; TAD: Transactivation domain). * indicates the two 
mutations that are found on the same allele in tumor #379. Stat3-C location is indicated 
in grey. b, STAT3 mutants L78R (L78), E166Q (E166), Y640F (Y640), D502Y K658Y 
(D502/K658), G656_Y657insF (G656), Y657_M660dup (Y657) and Stat3-C (SC) or control 
STAT3 wild-type (WT) and empty plasmid (EP) were transfected in Hep3B, HepG2 and 
Huh7 cells expressing a STAT3-driven luciferase (Luc) reporter construct. STAT3 
activation was measured after 6 hr of serum starvation and when indicated were treated 
for 3 hr with IL-6 (100 ng/ml). Shown is the Luc activity (mean) determined from triplicate 
co-transfections (± s.d.) relative to pSIEM-luc alone (EP) without IL-6. c, Graphs are 
qRT–PCR results showing the induction of endogenous CRP, STAT3 and SOCS3 
mRNA after overexpression of mutant STAT3 relative to unstimulated empty-plasmid-
transfected Hep3B cells (EP) (mean ± s.d.). d, Endogenous CRP mRNA expression in 
Hep3B cells transfected with increasing amounts of expression plasmids encoding WT 
or E166 STAT3 mutant (dotted line: mock-transfected cells). e, Activity of the STAT3 
mutants, including D502Y (D502), K658Y (K658) and the double mutant D502Y K658Y 
(D502/K658) were evaluated using STAT3-driven Luc in Hep3B cell line. Data are from 
triplicate transfections (± s.d.) relative to pSIEM-luc alone (EP). ns, not significant. *, ** 
and *** indicate differences between groups at P<0.05, P<0.01 and P<0.001, 
respectively (two-tailed t-test). 
 
Figure 2. Subcellular localization and role of tyrosine 705 phosphorylation in 
STAT3 IHCA mutants. a, Immunochemistry of phospho-STAT3-Y705 in STAT3-
mutated IHCA and adjacent non-tumor liver (NTL). b-d, Vectors driving the expression 
of STAT3 mutants, including L78R (L78), E166Q (E166), Y640F (Y640), G656_Y657insF 
(G656) or wild-type (WT) STAT3 were transfected into Hep3B cells. b, Expression of total 
and phosphorylated (pY705) STAT3 proteins were assessed by western blot and bands 
were quantified with ChemiDoc (Bio-Rad) using the Quantity One software; bars show 
the expression of pY705 STAT3 relative to total STAT3. c, d, Subcellular localization of 
total and phosphorylated (pY705) STAT3 proteins were analyzed by western blot (c) 
and by immunofluorescence (d). Results are representative of three independent 
experiments. Scale bars = 20 µm. e, CRP mRNA expression after transfection of wild-
type (WT), Y705F (Y705), Y640F (Y640), Y640F/Y705F (Y640/Y705), G656_Y657insF (G656) 
or G656_Y657insF/Y705F (G656/Y705) STAT3 in unstimulated Hep3B cells. Data are 
from triplicate transfections (± s.d.) relative to empty plasmid (EP). ns, not significant. *, 
** and *** indicate differences between groups at P<0.05, P<0.01 and P<0.001, 
respectively (two-tailed t-test).  
 
Figure 3. Dimerization of STAT3 IHCA mutants. a, Flag- and Myc-tagged constructs 
encoding either WT or mutant Y640 STAT3 were co-transfected (1:1) into Hep3B cells 
treated, or not, with IL-6 (100 ng/ml). STAT3 dimer formation was detected after 
immunoprecipitation using the anti-Flag antibody, followed by immunoblot (IB) analysis 
with Myc, Flag and pY705-STAT3 specific antibodies. Results are representative of 
three independent experiments. b, Effects of increasing WT STAT3 expression (wedge) 
on the constitutive activity of Y640 mutant STAT3 without IL-6. The graph plots the mean 
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level of expression of SOCS3 and CRP relative to cells transfected with EP (± s.d.). 
Units are plasmid µg. c, Several STAT3 IHCA mutations cluster near the transcription 
activation domain (TAD) of STAT3 (crystal structure PDB: 1BG1)(Becker et al., 1998). 
Residues 640, 656-660 (shown in green) that are mutated in IHCA tumors, the 
phosphorylated tyrosine (Tyr-705, black), as well as TAD residues 711-716 (blue) are 
shown in stick representation. One polypeptide chain and both TADs are shown as a 
cartoon. The two-fold related molecule, except the TAD, is shown as a surface 
representation. For residues of the TAD, Tyr-710 of the two-fold related molecule is 
labeled while residues 711-716 are not for clarity. d, DNA-binding activity of 10 µg of 
nuclear extracts of Hep3B cells engineered to express wild-type (WT), Y640 or G656 
STAT3 mutants. Bars indicate the DNA-binding activity to consensus STAT3 
oligonucleotides relative to activity measured in cells transfected with empty plasmid 
(EP). ns, not significant. *, ** and *** indicate differences between groups at P<0.05, 
P<0.01 and P<0.001, respectively (two-tailed t-test). Data are from triplicate 
transfections (± s.d.). 
 
Figure 4. Role of IL-6-JAK pathway and Src kinases on STAT3 IHCA mutant 
activation. STAT3 mutants Y640 and E166 were over-expressed in Hep3B cells. 
Activation of STAT3 is shown by luciferase (Luc) activity (mean) determined from 
triplicate transfections (± s.d.) relative to pSIEM-luc alone (EP) with serum starvation. a, 
Hep3B cells were exposed to increasing concentrations of IL-6. b. STAT3 mutants (E166 
and Y640) or empty vector (EP) were co-transfected with JAK1 siRNA (+) or control 
siRNA (-) into Hep3B cells exposed to IL-6 (100 ng/ml). c, STAT3 mutants (E166 and 
Y640) or empty vector (EP) were co-transfected with gp130 siRNA (+) or control siRNA (-
) into Hep3B cells. d. STAT3 mutants (E166 and Y640) or empty vector (EP) were co-
transfected with JAK2 siRNA (+) or control siRNA (-) into Hep3B cells. e. STAT3 
mutants (E166 and Y640) or empty vector (EP) were co-transfected with JAK1 siRNA (+) 
or control siRNA (-) into Hep3B cells. f. STAT3 mutants (E166 and Y640) or empty vector 
(EP) were transfected into Hep3B cells exposed to Src inhibitor 1 (SrcI-1) (10 µM, 9h). 
ns, not significant. *, ** and *** indicate differences between groups at P<0.05, P<0.01 
and P<0.001, respectively (two-tailed t-test). Data are from triplicate transfections (± 
s.d.). g, Expression profiles of STAT3 mutated IHCA and gp130 mutated IHCA. 
Comparison was carried out for the 28 genes validated by quantitative RT-PCR that 
were significantly differentially expressed between IHCA and non-tumorous livers. 5 
STAT3 mutated IHCA (in grey) were compared to 11 gp130 mutated IHCA (in white). 
Results are expressed as mean ± s.d.; differences between groups are not significant 
(two-tailed Mann-Whitney test). 
 
Supplementary Figure S1. Somatic DNA alterations identified on STAT3 gene and 
distribution of mutations according to the different isoforms. a-b, Selection of 
forwards and reverse sequences in three mutated IHCA (T) and their matching non-
tumor DNA (N) showing the somatic origin of all mutations identified (arrows). Amino 
acids and nucleotides are numbered according to STAT3 cDNA ORF. Sequences of 
cDNA show the expression of both normal and mutated STAT3 alleles in tumors. c, 
Schematic representation of STAT3 isoforms obtained by sequencing full-length cloned 
STAT3 cDNA from tumor #379 and according to the different protein domains (SH2: 
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Src-homology-2 domain; TAD: Transactivation domain). Mutations were harbored by all 
the different STAT3 isoforms, including or not splicing of nucleotides 2099-2101 leading 
to in-frame Ser701 deletion (S701del); and splicing of nucleotides 2145-2194 leading to 
a frame shift and a premature termination stop, eight codons downstream 
(p.Thr716PhefsX8) (STAT3β) (Schaefer et al., 1995). The two mutations 
(D502Y/K658Y) found are carried by the same allele. 
 
Supplementary Figure S2. a, Serine 727 phosphorylation of STAT3 mutants. 
Vectors driving the expression of STAT3 mutants, including L78R (L78), E166Q (E166), 
Y640F (Y640), or wild-type (WT) STAT3 were transfected into Hep3B cells. Expression of 
total and phosphorylated (pS727) STAT3 proteins were analyzed by western blot and 
the bands were quantified with ChemiDoc (Bio-Rad) using the Quantity One software. 
Bars show the expression of pS727 STAT3 relative to total STAT3. Results are 
representative of three independent experiments. b, Several STAT3 mutations in 
IHCA tumors reside near the TAD and Tyr-705. The crystal structure (PDB entry 
1bg1) reveals that several of residues mutated or duplicated in IHCA tumors (Tyr-640 
and 656-660) reside near the TAD. The DNA, one entire polypeptide chain, and both 
TADs are shown as a cartoon (bottom) and are colored as shown in the primary 
structure (top): the N-terminal domain that mediates cooperative DNA binding, grey, 
residues 1-130 and not part of the crystal structure; the coiled-coil domain, red, residues 
130-320; the DNA binding domain, orange, residues 321-465; a linker region, yellow, 
residues 466-585; the SH2 domain, green, residues 586-689; and the transcriptional 
activation domain (TAD), blue, residues 689-722. The crystallographically related 
residues 136-688 are shown as a surface representation; carbon atoms are in white, 
nitrogen in blue, oxygen in red, and sulfur in yellow. Residues mutated or duplicated in 
inflammatory tumors (166, 502, 640, 656-660) are shown as spheres (carbon in white, 
nitrogen in blue, and oxygen in red) and some are labeled. The phosphorylated tyrosine 
(Tyr-705) is also shown as a sphere in both two-fold related molecules with the carbon 
drawn in black. For clarity, residues labeled on the molecule shown in surface 
representation are identified by their residue number. c, Effect of IL-6 on STAT3 
mutant activity. Hep3B transfected with EP, WT or STAT3 mutants (L78, G656 or Y657) 
with or without IL-6 exposure (100 ng/ml). Graph plots the luciferase activity (Luc) 
relative to cells transfected with pSIEM-Luc alone (EP) ± s.d. (transfections in triplicate). 
ns, not significant. *, ** and *** indicate differences between groups at P<0.05, P<0.01 
and P<0.001, respectively (two-tailed t-test). 
 
Supplementary Figure S3. Effect of inhibitors on STAT3 IHCA mutants activation.  
a, Hep3B cells transfected with STAT3 mutants (E166 and Y640) or empty vector (EP) 
treated with 100 ng/ml of IL-6 were exposed 3 hr to increasing concentrations of AG490 
or 18 hr to increasing concentrations of Ruxolitinib. The graph plots the luciferase (Luc) 
activity relative to the transfected cells not treated with the inhibitor. b, Y640 STAT3 
mutant was over-expressed in Hep3B and exposed to increasing concentration of 
STAT3 inhibitor Curcumin during 24 hr. The graph plots the luciferase (Luc) activity 
relative to the transfected cells not treated with the inhibitor. c, STAT3 mutants E166 or 
Y640 were over-expressed in Hep3B and exposed to Src inhibitor 1 (SrcI-1) (10 µM, 9 hr) 
and IL-6 (100 ng/ml, during the last 3 hr of treatment). The graph plots the luciferase 
(Luc) activity relative to the transfected cells not treated with the inhibitor. d, STAT3 
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mutants E166 or Y640 were over-expressed in Hep3B and exposed to Src inhibitor 5 (SrcI-
5) or to PP2, 10 µM during 9 hr. The graph plots the luciferase (Luc) activity relative to 
the transfected cells not treated with the inhibitor. All results are from triplicate 
transfections (± s.d.) relative to pSIEM-luc alone (EP) with serum starvation. ns, not 
significant. *, ** and *** indicate differences between groups at P<0.05, P<0.01 and 
P<0.001, respectively (two-tailed t-test). e, Vectors driving the expression of Y640F 
(Y640) STAT3 mutant or empty vector (EP) were transfected into Hep3B cells and 
exposed to Src inhibitor 1 (SrcI-1) (10 µM, 9 hr) and IL-6 (100 ng/ml, during the last 3 hr 
of treatment). Expression of total and phosphorylated (pY705) STAT3 proteins were 
analyzed by western blot. f, Knockdown efficiency by JAK1 siRNA. Hep3B cells were 
co-transfected with Y640 STAT3 mutant or empty vector (EP) and JAK1 siRNA (+) or 
control siRNA (-). Shown is the endogenous JAK1 mRNA expression determined from 
triplicate transfections (± s.d.) relative to EP with serum starvation. Remaining JAK1 
expression in JAK1 siRNA transfected cells was less than 20% of control. 
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Table 1. STAT3 somatic mutations identified in inflammatory 
hepatocellular tumours 
    
Tumours Nucleotide change Amino acid change Mutant ID 
CHC341T T233>G L78>R L
78
 
CHC379T 
G1504>T D502>Y D
502
 
A1972>T; G1974>T K658>Y K
658
 
CHC574T G496>C E166>Q E
166
 
CHC966T A1919>T Y640>F Y
640
 
CHC1021T T1969_G1980dup Y657_M660dup Y
657
 
CHC1351T C1968>T; 1969_1970insTTT G656_Y657insF G
656
 
        
Codons and mutated nucleotides are numbered according to STAT3 cDNA ORF   
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Supplementary Table S1. TaqMan® pre-designed gene expression assays 
used for quantitative RT-PCR analyses 
Assay ID 
Gene 
Symbol 
Gene Name 
Hs99999901_s1 18S Eukaryotic 18S rRNA 
Hs00187845_m1 BCL2A1 BCL2-related protein A1 
Hs00154109_m1 BIRC3 baculoviral IAP repeat-containing 3 
Hs00355476_m1 CCL20 chemokine (C-C motif) ligand 20 
Hs00265044_m1 CRP C-reactive protein, pentraxin-related 
Hs00170586_m1 FGB fibrinogen beta chain 
Hs00221783_m1 HAMP Hepcidin 
Hs00153153_m1 HIF1A hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 
Hs00219575_m1 HLA-DRA major histocompatibility complex, class II, DR alpha 
Hs00428366_m1 HLA-E major histocompatibility complex, class I, E 
Hs00166223_m1 IFNGR1 interferon gamma receptor 1 
Hs00194264_m1 IFNGR2 interferon gamma receptor 2 
Hs00985639_m1 IL6 interleukin 6 (interferon, beta 2) 
Hs01075667_m1 IL6R interleukin 6 receptor 
Hs00185375_m1 IRF7 interferon regulatory factor 7 
Hs00196051_m1 ISGF3G interferon-stimulated transcription factor 3, gamma 
Hs00234567_m1 JAK2 Janus kinase 2 
Hs00544758_m1 PMSB8 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7) 
Hs00544762_m1 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) 
Hs01667582_m1 SAA2 serum amyloid A2 
Hs00705164_s1 SOCS1 suppressor of cytokine signaling 1 
Hs00269575_s1 SOCS3 suppressor of cytokine signaling 3 
Hs00162154_m1 SPINK1 serine peptidase inhibitor, Kazal type 1 
Hs00234829_m1 STAT1 signal transducer and activator of transcription 1, 91kDa 
Hs00237139_m1 STAT2 signal transducer and activator of transcription 2, 113kDa 
Hs00374280_m1 STAT3 signal transducer and activator of transcription 3 (acute-phase response factor) 
Hs00388682_m1 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
Hs00900055_m1 VEGFA vascular endothelial growth factor A 
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Supplementary Table S2. List of primers used in PCR and 
sequencing 
F: forward primer; R: reverse primers  
localisation Sequence Primer name 
STAT3 cDNA amplification 
22 bp upstream of exon 1 TGGGACCCCTGATTTTAGCA 1F-STAT3 
92 bp downstream of stop TTCAGATGATCTGGGGTTTGG 4R-STAT3 
STAT3 cDNA sequencing 
22 bp upstream of exon 1 TGGGACCCCTGATTTTAGCA 1F-STAT3 
exon 6 TCACTCACGATGCTTCTCCG 1R-STAT3 
exon 5 CCTCAAGAGTCAAGGAGACAT 2F-STAT3 
exon 12 CCTCAGGGTCAAGTGTTTGAA 2R-STAT3 
exon 11 TCTCAGAGGATCCCGGAAATT 3F-STAT3 
exon 19 CCTCCTTCTTTGCTGCTTTCA 3R-STAT3 
exon 18 AAAGTACATCCTGGCCCTTTG 4F-STAT3 
92 bp downstream of stop TTCAGATGATCTGGGGTTTGG 4R-STAT3 
STAT3 gDNA amplification and sequencing 
intron 1 GAATGGGTTATAGCATCAGG STAT3-ADNg-ex2-F 
intron 2 CTCAGGTAATGATGCTCACG STAT3-ADNg-ex2-R 
intron 4  TTTTCTGTTCCCAAGGAAAT STAT3-ADNg-ex5-F 
intron 5 CCCGCCTTAAGATCTAAACAGA STAT3-ADNg-ex5-R 
intron 14 CCCCACTCCCTCCGCAGACC STAT3-ADNg-ex16-F 
intron 16 GCGGGAGGGAGAAGGGGTGAA STAT3-ADNg-ex16-R 
intron 19 TGGGCAGTTTTCTCTGAGATGACCT STAT3-ADNg-ex20-F 
intron 20 CCCCCAGGTTATTCAGGCATTTG STAT3-ADNg-ex20-R 
intron 20 TGGCTTCCTCCAGCTCTGCTTACTG STAT3-ADNg-ex21-22-F 
intron 22 GAGCATCACACAAAGGGGACCAACT STAT3-ADNg-ex21-22-R 
intron 22 GCCTGGGCCCTGTCCTCTGAA STAT3-ADNg-ex23-F 
intron 23 TGGGGTTTGGCTGTGTGAGGG STAT3-ADNg-ex23-R 
 
  
STAT3 mutations in hepatocellular adenoma 29 
Supplementary Table S3. List of primers used in site-directed mutagenesis 
STAT3 c.233T>G p.L78R  
STAT3 c.233T>G p.L78R -F 5'-tgcaagagtcgaatgttcgctatcagcacaatctacg-3' 
STAT3 c.233T>G p.L78R -R 5'-cgtagattgtgctgatagcgaacattcgactcttgca-3' 
  
STAT3 c.496G>C p.E166Q  
STAT3 c.496G>C p.E166Q -F 5'-gatctagaacagaaaatgaaagtggtacagaatctccaggatg-3' 
STAT3 c.496G>C p.E166Q -R 5'-catcctggagattctgtaccactttcattttctgttctagatc-3' 
  
STAT3 c.1504G>T p.D502Y  
STAT3 c.1504G>T p.D502Y -F 5'-ccaattggaacctggtatcaagtggccgagg-3' 
STAT3 c.1504G>T p.D502Y -R 5'-cctcggccacttgataccaggttccaattgg-3' 
  
STAT3 c.1972_1974delinsTAT p.K658Y  
STAT3 c.1972_1974delinsTAT p.K658Y -F 5'-ttgctgaaatcatcatgggctattatatcatggatgctaccaatatcc-3' 
STAT3 c.1972_1974delinsTAT p.K658Y -R 5'-ggatattggtagcatccatgatataatagcccatgatgatttcagcaa-3' 
  
STAT3 c.1919A>T p.Y640F  
STAT3 c.1919A>T p.Y640F -F 5'-cagtccgtggaaccattcacaaagcagcagct-3' 
STAT3 c.1919A>T p.Y640F -R 5'-agctgctgctttgtgaatggttccacggactg-3' 
  
STAT3 c.1969_1980dup p.Y657_M660dup  
STAT3 c.1969_1980dup p.Y657_M660dup -F 5'-tttgctgaaatcatcatgggctataagatcatgtataagatcatggatgctacc-3' 
STAT3 c.1969_1980dup p.Y657_M660dup -R 5'-ggtagcatccatgatcttatacatgatcttatagcccatgatgatttcagcaaa-3' 
  
STAT3 c.1968delinsTTTT p.G656_Y657insF  
STAT3 c.1968delinsTTTT p.G656_Y657insF -F 5'-ttgctgaaatcatcatgggtttttataagatcatggatgctac-3' 
STAT3 c.1968delinsTTTT p.G656_Y657insF -R 5'-gtagcatccatgatcttataaaaacccatgatgatttcagcaa-3' 
  
STAT3 p.Y705F  
STAT3 p.Y705F -F 5'-gtagcgctgccccattcctgaagaccaag-3' 
STAT3 p.Y705F -R 5'-cttggtcttcaggaatggggcagcgctac-3' 
  
STAT3-Flag  
STAT3-Flag -F 5'-gctacctcccccatggattataaagatgatgatgataaatgagggccctatggagctgagaacgg-3' 
STAT3-Flag -R 5'-gttctcagctccatagggccctcatttatcatcatcatctttataatccatgggggaggtagcgc-3' 
  
STAT3-Myc  
STAT3-Myc -F 5'-gctacctcccccatggaacaaaaacttatttctgaagaagatctttgagggccctatggagctgagaacgg-3' 
STAT3-Myc -R 5'-gttctcagctccatagggccctcaaagatcttcttcagaaataagtttttgttccatgggggaggtagcgc-3' 
 
 
